Krystal Biotech, Inc. (NASDAQ:KRYS)
Stock Price:
$80.58
-1.13
(-1.38%)
Updated
Feb 2, 2023 09:00 PM GMT+0000
Overview
Financials
Statistics
Profile
Chart
| Market Cap | 2.07B |
|---|---|
| Revenue | 0 |
| Gross Profit | 0 |
| Shares Out | 25.75M |
| EPS (ttm) | |
| PE Ratio | 0.0000 |
| Forward PE | -16.9866 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Feb 2 |
|---|---|
| Last Price | $80.58 |
| Previous Close | $81.71 |
| Change ($) | -1.13 |
| Change (%) | -1.38% |
| Day's Open | 82.06 |
| Day's Range | Market Closed |
| Day's Volume | 273.53K |
| 52 Week Range | 47.67 - 85.65 |
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
News
Quick info
Country
United States
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
CEO
Krish S. Krishnan
Address
2100 Wharton St Ste 701
Pittsburgh
Pennsylvania
15203
Pittsburgh
Pennsylvania
15203
Phone
14125865830
Website
www.krystalbio.com
Ticker Symbol
KRYS
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Krystal Biotech, Inc. income statements (2020) (USD)
| June 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | 394K | 394K | 361K | 361K |
| Gross Profit | -394K | -394K | -361K | -361K |
| Research & Development | 3.64M | 3.64M | 3.53M | 3.53M |
| Selling General & Admin | 2.92M | 2.92M | 2.06M | 2.06M |
| Operating Expense | 6.95M | 6.95M | 5.95M | 5.95M |
| Operating Income | -6.95M | -6.95M | -5.95M | -5.95M |
| Other Income Expense Net | 121K | 121K | 605K | 605K |
| EBIT | -6.95M | -6.95M | -5.95M | -5.95M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -6.83M | -6.83M | -5.34M | -5.34M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -6.83M | -6.83M | -5.34M | -5.34M |
| Net Income Basic | -6.83M | -6.83M | -5.34M | -5.34M |
Krystal Biotech, Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | 276K | 259K | 240K | 199K |
| Gross Profit | -276K | -259K | -240K | -199K |
| Research & Development | 4.35M | 3.89M | 4.22M | 3.17M |
| Selling General & Admin | 1.53M | 1.20M | 1.43M | 1.33M |
| Operating Expense | 6.15M | 5.34M | 5.89M | 4.69M |
| Operating Income | -6.15M | -5.34M | -5.89M | -4.69M |
| Other Income Expense Net | 797K | 1.07M | 542K | 583K |
| EBIT | -6.15M | -5.34M | -5.89M | -4.69M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -5.36M | -4.27M | -5.35M | -4.11M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -5.36M | -4.27M | -5.35M | -4.11M |
| Net Income Basic | -5.36M | -4.27M | -5.35M | -4.11M |
Krystal Biotech, Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | 61K | 38K | 23K | 18K |
| Gross Profit | -61K | -38K | -23K | -18K |
| Research & Development | 2.80M | 1.91M | 1.53M | 1.52M |
| Selling General & Admin | 1.36M | 1.02M | 0.90M | 739K |
| Operating Expense | 4.22M | 2.97M | 2.45M | 2.28M |
| Operating Income | -4.22M | -2.97M | -2.45M | -2.28M |
| Other Income Expense Net | 511K | 217K | 173K | 127K |
| EBIT | -4.22M | -2.97M | -2.45M | -2.28M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -3.71M | -2.76M | -2.28M | -2.15M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -3.71M | -2.76M | -2.28M | -2.15M |
| Net Income Basic | -3.71M | -2.76M | -2.28M | -2.15M |
Krystal Biotech, Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | N.A | N.A | N.A |
| Cost of Revenue | 14K | 5K | 3K |
| Gross Profit | -14K | -5K | -3K |
| Research & Development | 1.09M | 1.36M | 446K |
| Selling General & Admin | 396K | 733K | 266K |
| Operating Expense | 1.50M | 2.09M | 715K |
| Operating Income | -1.5M | -2.09M | -715K |
| Other Income Expense Net | 105K | -3.18M | -44K |
| EBIT | -1.5M | -2.09M | -715K |
| Interest Income | N.A | 3.18M | 44K |
| Pretax Income | -1.39M | -5.27M | -759K |
| Income Tax | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Net Income | -1.39M | -5.27M | -759K |
| Net Income Basic | -1.39M | -5.27M | -759K |
Krystal Biotech, Inc. balance sheet (2020) (USD)
| June 2020 | March 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 291.68M | 180.23M | 180.23M |
| Receivables | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A |
| Current Assets | 298.54M | 188.33M | 188.33M |
| Other Current Assets | 1.37M | 1.63M | 1.63M |
| Short Term Investments | 5.50M | 6.48M | 6.48M |
| Long Term Investments | N.A | N.A | N.A |
| Property/Plant Equipment | 15.77M | 12.90M | 12.90M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 309.70M | 198.37M | 198.37M |
| Other Assets | 3.84M | 3.91M | 3.91M |
| Total Assets | 318.15M | 205.13M | 205.13M |
| Accounts Payable | 1.61M | 636K | 636K |
| Other Current Liabilities | 3.68M | 2.92M | 2.92M |
| Total Current Liabilities | 5.83M | 4.06M | 4.06M |
| Total Liabilities | 8.45M | 6.76M | 6.76M |
| Long Term Debt | 2.62M | 2.70M | 2.70M |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 19.66M | 17.37M | 17.37M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -51.22M | -44.39M | -44.39M |
| Capital Surplus | 360.88M | 242.73M | 242.73M |
| Shareholder Equity | 309.70M | 198.37M | 198.37M |
| Other Liabilities | N.A | N.A | N.A |
Krystal Biotech, Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 187.51M | 194.81M | 186.59M | 98.01M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 195.88M | 204.44M | 196.20M | 107.89M |
| Other Current Assets | 2.20M | 1.23M | 737K | 1.26M |
| Short Term Investments | 6.17M | 8.40M | 8.88M | 8.62M |
| Long Term Investments | 497K | N.A | N.A | N.A |
| Property/Plant Equipment | 11.18M | 9.66M | 8.87M | 7.36M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 202.91M | 207.65M | 198.29M | 109.49M |
| Other Assets | 1.46M | 138K | 86K | 455K |
| Total Assets | 209.02M | 214.23M | 205.16M | 115.70M |
| Accounts Payable | 724K | 1.25M | 896K | 1.13M |
| Other Current Liabilities | 2.12M | 2.01M | 2.61M | 1.70M |
| Total Current Liabilities | 3.33M | 3.73M | 3.94M | 3.24M |
| Total Liabilities | 6.11M | 6.59M | 6.87M | 6.22M |
| Long Term Debt | 2.78M | 2.86M | 2.93M | 2.98M |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 17.35M | 17.31M | 16.95M | 14.44M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -39.05M | -33.69M | -29.42M | -24.07M |
| Capital Surplus | 241.95M | 241.33M | 227.69M | 133.54M |
| Shareholder Equity | 202.91M | 207.65M | 198.29M | 109.49M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Krystal Biotech, Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 103.67M | 46.67M | 41.81M | 47.23M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 112.65M | 52.82M | 45.71M | 47.67M |
| Other Current Assets | 889K | 527K | 260K | 441K |
| Short Term Investments | 8.09M | 5.63M | 3.64M | N.A |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | 3.01M | 1.63M | 256K | 182K |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 113.23M | 52.29M | 45.27M | 47.40M |
| Other Assets | 452K | N.A | 64K | N.A |
| Total Assets | 116.12M | 54.45M | 46.03M | 47.85M |
| Accounts Payable | 888K | 378K | 214K | 89K |
| Other Current Liabilities | 1.71M | 1.54M | 545K | 363K |
| Total Current Liabilities | 2.60M | 1.92M | 759K | 452K |
| Total Liabilities | 2.89M | 2.16M | 759K | 452K |
| Long Term Debt | N.A | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 14.43M | 10.98M | 10.35M | 10.31M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -19.96M | -16.25M | -13.5M | -11.22M |
| Capital Surplus | 133.18M | 68.54M | 58.77M | 58.62M |
| Shareholder Equity | 113.23M | 52.29M | 45.27M | 47.40M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Krystal Biotech, Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 49.59M | 52.57M | 3.52M |
| Receivables | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A |
| Current Assets | 49.91M | 52.62M | 3.64M |
| Other Current Assets | 323K | 48K | 124K |
| Short Term Investments | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A |
| Property/Plant Equipment | 200K | 55K | 48K |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 49.47M | 50.20M | -829K |
| Other Assets | N.A | N.A | 287K |
| Total Assets | 50.11M | 52.67M | 3.98M |
| Accounts Payable | 193K | 550K | 260K |
| Other Current Liabilities | 447K | 1.93M | 404K |
| Total Current Liabilities | 640K | 2.48M | 4.81M |
| Total Liabilities | 640K | 2.48M | 4.81M |
| Long Term Debt | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | 4.14M |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 10.31M | 10.24M | 10.24M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -9.07M | -7.68M | -2.4M |
| Capital Surplus | 58.54M | 57.88M | 168K |
| Shareholder Equity | 49.47M | 50.20M | -829K |
| Other Liabilities | N.A | N.A | N.A |
Krystal Biotech, Inc. cash flow (2020) (USD)
| June 2020 | March 2020 | |
|---|---|---|
| Net Income | -6.83M | -5.34M |
| Depreciation | 523K | 361K |
| Changes in Receivables | N.A | N.A |
| Changes in Inventories | N.A | N.A |
| Cash Change | 111.45M | -7.29M |
| Cash Flow | -4.96M | -6.23M |
| Capital Expenditures | -1.95M | -1.51M |
| Investments | 1M | 203K |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | -0.95M | -1.31M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | -105K | N.A |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | 117.36M | 243K |
| Exchange Rate Effect | N.A | N.A |
Krystal Biotech, Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -5.36M | -4.27M | -5.35M | -4.11M |
| Depreciation | 276K | 259K | 240K | 199K |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -7.29M | 8.22M | 88.57M | -5.66M |
| Cash Flow | -7.05M | -4.24M | -4.21M | -3.22M |
| Capital Expenditures | -2.28M | -1.18M | -0.98M | -1.97M |
| Investments | 1.73M | 470K | -261K | -512K |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -545K | -705K | -1.24M | -2.48M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 299K | 13.17M | 94.02M | 40K |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Krystal Biotech, Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -3.71M | -2.76M | -2.28M | -2.15M |
| Depreciation | 61K | 38K | 24K | 18K |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | 57M | 4.85M | -5.42M | -2.36M |
| Cash Flow | -3.52M | -1.94M | -1.62M | -2.37M |
| Capital Expenditures | -1.3M | -832K | -162K | N.A |
| Investments | -2.46M | -1.99M | -3.64M | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -3.77M | -2.76M | -3.8M | N.A |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 64.29M | 9.55M | 4K | 6K |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Krystal Biotech, Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -1.39M | -5.27M | -759K |
| Depreciation | 14K | 5K | 3K |
| Changes in Receivables | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A |
| Cash Change | -2.98M | 49.05M | 1.56M |
| Cash Flow | -2.13M | -1.1M | -408K |
| Capital Expenditures | -159K | -12K | -32K |
| Investments | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -159K | -12K | -32K |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | 2M |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | -693K | 50.16M | 2M |
| Exchange Rate Effect | N.A | N.A | N.A |
Krystal Biotech, Inc. dividends (USD)
Total Valuation
Krystal Biotech Inc has a market cap or net worth of $2.07 billion. The enterprise value is $0.
Market Cap
2.07B
Enterprise Value
0
Important Dates
Earnings Date
Feb 27, 2023
Ex-Dividend Date
n.a
Share Statistics
Krystal Biotech Inc has 25.75 million shares outstanding.
Shares Outstanding
25.75M
Float
n.a
Valuation Ratios
The trailing PE ratio is 0.0000 and the forward PE ratio is -16.9866. Krystal Biotech Inc's PEG ratio is 0.0000.
PE Ratio
n.a
Forward PE
-16.9866
PS Ratio
n.a
PB Ratio
n.a
PEG Ratio
n.a
Stock Price Statistics
The stock price has increased by 0.0172%. The beta is 1.4125, so Krystal Biotech Inc's price volatility has been higher than the market average.
Beta (1Y)
1.4125
52-Week Price Change
+0.0172%
50-Day Moving Average
79.71
200-Day Moving Average
74.55
Average Volume (30 Days)
210.46K
Income Statement
In the last 12 months, Krystal Biotech Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.
Revenue
0
Gross Profit
0
EBITDA
0
Earnings per Share
About
Ticker Symbol
KRYS
Reporting Currency
USD
Key Executives
Chien Jennifer
Chief Commercial Officer
ORTH ANDREW C.
Chief Commercial Officer
Krishnan Krish S
President and CEO
Krishnan Suma
Chief Operating Officer